Phuturdex › Diseases › Relapsing-remitting multiple sclerosis
Drugs in development · updated 30 October 2026
Relapsing-remitting multiple sclerosis: drugs in development
As of 30 October 2026 there are 25 active clinical trials (recruiting or ongoing, phases I–III) on 26 drugs for relapsing-remitting multiple sclerosis. 8 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| IMU-838 | III | 2 | NCT05201638 |
| ABP 692 | III | 1 | NCT06700343 |
| BCD-281 | III | 1 | NCT07321093 |
| CT-P53 | III | 1 | NCT05906992 |
| RHuPH20 | II | 2 | NCT07503340 |
| Ifenprodil | II | 1 | NCT06330077 |
| Rocbrutinib | II | 1 | NCT07776743 |
| Terfenadine | II | 1 | NCT07827716 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| OcrelizumabOcrevus | III | 8 | NCT04544436 |
| RituximabRuxience, Rituxan | III | 5 | NCT04688788 |
| MethylprednisoloneMethylprednisolon, Methylprenisolone | III | 3 | NCT04544436 |
| FingolimodGilenya®, Fingolimod Accord® | III | 2 | NCT06408259 |
| AcetaminophenParacetamol, APAP | III | 1 | NCT04688788 |
| BIIB017 | III | 1 | NCT03958877 |
| FexofenadineChildren'S Allegra Hives®, Children'S Allegra Allergy® | III | 1 | NCT04688788 |
| Glatiramer AcetateCopaxone® | III | 1 | NCT07189325 |
| OfatumumabKesimpta®, Arzerra® | III | 1 | NCT07189325 |
| OzanimodZeposia® | III | 1 | NCT06408259 |
| TeriflunomideAubagio®, Teriflunomide Viatris (previously Teriflunomide Mylan)® | III | 1 | NCT07189325 |
| Cladribine2-chlorodeoxyadenosine, Mavenclad® | II | 1 | NCT07517185 |
| Clemastine FumarateTavist-1®, Tavist® | I–II | 1 | NCT05359653 |
| Dimethyl FumarateTecfidera®, Dimethyl fumarate Mylan® | II | 1 | NCT07776743 |
| RemibrutinibLOU064, Rhapsido® | II | 1 | NCT07222956 |
Sorted by most advanced phase and number of active trials. Showing 15 of 18 drugs.
All 26 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Broader categories
- Immune System Diseases 54 drugs
- Autoimmune disease 94 drugs
- Nervous System Diseases 39 drugs
- Autoimmune disease of the nervous system 21 drugs
- Demyelinating disease 6 drugs
- Multiple sclerosis 93 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D020529 “Multiple Sclerosis, Relapsing-Remitting”.